Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Engineered Treg
- Development stage
- Preclinical
- Lead developer
- Taiwan Bio Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Engineered Treg is a preclinical-stage cell therapy being developed by TaiwanBio Therapeutics for the treatment of autoimmune diseases. This therapeutic candidate utilizes the company's proprietary FAST CGT platform to genetically modify regulatory T cells (Tregs), aiming to enhance their stability, specificity, or immunosuppressive potency. By leveraging the natural role of Tregs in maintaining immune homeostasis, the therapy is designed to restore self-tolerance and modulate the aberrant immune responses that drive various autoimmune conditions.
- Other names
- Engineered regulatory T cell therapyTaiwanBio Therapeutics Engineered Treg
Beyond the preview
Go deeper on Engineered Treg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Engineered Treg.